देश: कनाडा
भाषा: अंग्रेज़ी
स्रोत: Health Canada
IPRATROPIUM BROMIDE
MYLAN PHARMACEUTICALS ULC
R03BB01
IPRATROPIUM BROMIDE
250MCG
SOLUTION
IPRATROPIUM BROMIDE 250MCG
INHALATION
20ML
Prescription
ANTIMUSCARINICS ANTISPASMODICS
Active ingredient group (AIG) number: 0115643001; AHFS:
CANCELLED POST MARKET
2018-07-12
PAGE 1 OF 34 PRODUCT MONOGRAPH PR MYLAN-IPRATROPIUM STERINEBS AND PR MYLAN-IPRATROPIUM SOLUTION (Ipratropium Bromide Inhalation Solution) 0.025% (250 μ g/mL) BRONCHODILATOR Mylan Pharmaceuticals ULC 37 Advance Road Etobicoke, Ontario DATE OF REVISION: Canada M8Z 2S6 December 15, 2010 Control number: 142044 PAGE 2 OF 34 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION........................................................ 3 SUMMARY PRODUCT INFORMATION................................................................................ 3 INDICATIONS AND CLINICAL USES ................................................................................... 3 CONTRAINDICATIONS .......................................................................................................... 4 WARNINGS AND PRECAUTIONS ......................................................................................... 4 ADVERSE REACTIONS........................................................................................................... 6 DRUG INTERACTIONS ........................................................................................................... 9 DOSAGE AND ADMINISTRATION ....................................................................................... 9 OVERDOSAGE ....................................................................................................................... 10 ACTION AND CLINICAL PHARMACOLOGY.................................................................... 11 STORAGE AND STABILITY ................................................................................................. 14 SPECIAL HANDLING INSTRUCTIONS............................................................................... 14 DOSAGE FORMS, COMPOSITION AND PACKAGING ..................................................... 15 PART II: SCIENTIFIC INFORMATION .............................................................................. 16 PHARMACEUTICAL INFORMATION........................................................... पूरा दस्तावेज़ पढ़ें